Stay up-to-date on best practices in managing asparaginase treatment in patients with acute lymphoblastic leukemia (ALL). Drs Patrick Brown, MD, and Stacy Cooper, MD, discuss, in depth, a recent consensus publication focusing on the identification and management of hypersensitivity reactions in pediatric patients receiving asparaginase treatment. Watch this CME-certified activity for expert perspectives in patient management.
0.5 AMA PRA Category 1 Credit™
Nov 30, 2017
Dec 2, 2018
Patrick Brown, MDJohns Hopkins University School of Medicine
Baltimore, Maryland, United States
Stacy Cooper, MDJohns Hopkins University School of Medicine
Baltimore, Maryland, United States
This educational activity is designed to meet the needs of hematologists and other healthcare professionals involved in the treatment of patients with ALL.
After successful completion of this educational activity, participants should be able to:
- Discuss best practices for assessing asparaginase activity in patients with ALL
- Develop management strategies to treat patients with ALL who develop clinical allergic reactions on asparaginase therapy
- Implement recommended best practices to manage patients with ALL who develop “silent inactivation” of asparaginase activity
This educational activity is supported by a grant from Jazz Pharmaceuticals.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Brown has disclosed that he has membership on advisory committees or review panels for Novartis Oncology and Shire. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Cooper has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of prIME Oncology have disclosed:
- Briana Betz, PhD (scientific content manager) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.